Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pilot Study on the Impact of Polymorphisms Linked to Multi-Kinase Inhibitor Metabolism on Lenvatinib Side Effects in Patients with Advanced Thyroid Cancer.

International journal of molecular sciences - 13 Mar 2023

Cantara Silvia, Dalmiglio Cristina, Marzocchi Carlotta, Sagnella Alfonso, Brilli Lucia, Trimarchi Andrea, Maino Fabio, Valerio Laura, Castagna Maria Grazia

Abstract excerpt

Multi-kinase inhibitors (MKIs) represent the best therapeutic option in advanced thyroid cancer patients. The therapeutic efficacy and toxicity of MKIs are very heterogeneous and are difficult to predict before starting treatment. Moreover, due to the development of severe adverse events, it is necessary to interrupt the therapy some patients. Using a pharmacogenetic approach, we evaluated polymorphisms in genes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cytochrome P-450 CYP3A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug-Related Side Effects and Adverse Reactions

Share to Hypertension

Share to Iatrogenic Disease

Share to Pilot Projects

Share to Protein Kinase Inhibitors

Share to Thyroid Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 36982571
DOI: 10.3390/ijms24065496
PMCID: PMC10049548

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pilot Study on the Impact of Polymorphisms Linked to Multi-Kinase Inhibitor Metabolism on Lenvatinib Side Effects in Patients with Advanced Thyroid Cancer.PMID 36982571Read ↗

Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancerSemantic proximity Read ↗

PharmGKB summary: very important pharmacogene information for CYP3A5.Semantic proximity Read ↗

Association between pharmacokinetics of lenvatinib in healthy subjects and genetic polymorphisms of ABCB1 3435C>T and ABCB1 2677G>T/A.Semantic proximity Read ↗

Clinical effects of single nucleotide polymorphisms on drug-related genes in Japanese metastatic renal cell carcinoma patients treated with sunitinib.Semantic proximity Read ↗

Influences of ABC transporter and CYP3A4/5 genetic polymorphisms on the pharmacokinetics of lenvatinib in Chinese healthy subjects.Semantic proximity Read ↗

ABCG2 Polymorphism rs2231142 and hypothyroidism in metastatic renal cell carcinoma patients treated with sunitinib.Semantic proximity Read ↗

Clinical implications of germline variations for treatment outcome and drug resistance for small molecule kinase inhibitors in patients with non-small cell lung cancer.Semantic proximity Read ↗

Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients.Semantic proximity Read ↗

Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity.Semantic proximity Read ↗

Genetic Variants in the ABCB1 and ABCG2 Gene Drug Transporters Involved in Gefitinib-Associated Adverse Reaction: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Genetic factors affecting drug disposition in Asian cancer patients.Semantic proximity Read ↗

Pharmacogenetics of small-molecule tyrosine kinase inhibitors: Optimizing the magic bullet.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.